MILFORD, Mass.--(BUSINESS WIRE)--SeraCare Life Sciences, Inc. (SRLS:PK) today presented data demonstrating that the Company’s seroconversion panels for HIV, Hepatitis B virus (HBV) and Hepatitis C virus (HCV) remain stable for a minimum of 25 years. This extended shelf-life expands research opportunities for biopharmaceutical customers who are developing life-saving products and allows in vitro diagnostic (IVD) companies to benchmark improvements in assay development for HIV, HBV and HCV. Seroconversion panels are plasma specimens collected from a single donor during the development of viral infection and the subsequent immune response.
